Explain molecular oncogenesis, genomic instability, epithelial precancer, invasion and biomarker logic in O&G cancers.

Molecular Oncogenesis, Genomic Instability and O&G Cancer Pathology

Start with one sentence: cancer is a cell that no longer obeys its tissue. A healthy epithelial cell divides only when its surroundings permit it, stays where it belongs, and dies on cue when it is damaged or surplus. Cancer is what happens when a single cell accumulates enough heritable changes to ignore all three of those rules at once — it proliferates without permission, refuses to die, and eventually crosses the boundary that should contain it. Everything else in this chapter is detail hung on that one idea.

So cancer is not simply "rapid growth". It is a clonal tissue ecosystem: a population descended from one rule-breaking ancestor cell, acquiring further advantages, recruiting stroma and blood vessels, dodging immunity, breaching the basement membrane, and sometimes seeding distant sites. In O&G, that biology becomes practical very quickly. HPV screening detects a viral driver before invasion. BRCA and homologous-recombination-deficiency (HRD) status predict platinum and PARP-inhibitor vulnerability. Mismatch-repair loss explains Lynch syndrome and immunotherapy responsiveness. And p16 or p53 immunostaining turns a vague biopsy into a lineage diagnosis.

The Primary candidate needs the mechanism layer below the clinical algorithms, and it follows a single storyline:

normal cell control -> driver alteration -> clonal expansion -> precancer -> invasion -> spread -> biomarker-directed interpretation

We will walk that line from left to right. Each section assumes only the one before it, so by the time the molecular labels appear (p53-abnormal, MMR-deficient, HRD-positive), you will already understand the broken machinery they name.

First, the Words: Neoplasia, Benign and Malignant

Before mechanisms, fix the vocabulary, because the exam and the pathology report both use it precisely.

Neoplasia is new, autonomous growth — a clone that keeps proliferating after the normal stimulus has gone. A tumour is simply a mass; not every mass is a neoplasm (a cyst or an abscess is a tumour-as-swelling but not neoplastic), and not every neoplasm forms an obvious lump.

A neoplasm is benign or malignant, and the dividing line is behaviour, not speed:

Nomenclature encodes the lineage. A benign epithelial or glandular growth takes the -oma suffix (leiomyoma, adenoma); a malignant epithelial growth is a carcinoma (squamous cell carcinoma, adenocarcinoma); a malignant connective-tissue growth is a sarcoma (leiomyosarcoma); blood and lymphoid malignancies are leukaemias and lymphomas. In the female genital tract almost everything epithelial is müllerian-derived, so a carcinoma arising anywhere along the tract can recapitulate any müllerian epithelial phenotype — serous, endometrioid, mucinous or clear-cell — which is why ovarian, tubal and endometrial cancers share so much biology.

This vocabulary is the foundation for the rest of the chapter: every later label (dysplasia, intraepithelial neoplasia, invasive carcinoma) is a point along the benign-to-malignant continuum.

The Normal Cell Has Brakes, Instructions and Repair Crews

With the words fixed, return to the cell that still obeys its tissue. A normal epithelial cell divides only when the context permits it. Growth factors, adhesion signals, polarity, oxygen supply, immune surveillance and DNA-damage checkpoints all decide whether the cell should divide, pause, differentiate, repair, senesce or die.

The exam mistake is to define cancer by one mutation. Most cancers require several cooperating changes. A single HPV infection, PTEN loss or BRCA variant is a risk state or initiating event; cancer emerges when enough restraints fail in the right tissue context.

How the Brakes Actually Work: the Cell Cycle and Two Ways to Die

Two of those restraints — the cell-cycle checkpoints and programmed cell death — deserve a closer look, because cancer biology and cancer treatment both target them directly.

A dividing cell moves through an ordered cycle: G1 (growth and the decision to divide), S (DNA replication), G2 (preparation), and M (mitosis). At the boundaries sit checkpoints that ask whether conditions are safe to proceed. The G1/S checkpoint, governed by the Rb protein and supervised by p53, is the most important for oncology: if DNA is damaged, p53 halts the cycle to allow repair, drives the cell into permanent arrest (senescence) if damage is severe, or triggers its death. This is why p53 is called the guardian of the genome, and why its loss is so dangerous — a damaged cell is allowed to replicate its errors instead of pausing or dying.

When a cell must die, it can do so in two fundamentally different ways:

Apoptosis is the relevant death for cancer. Normal tissue uses it constantly — to sculpt the embryo, to shed the endometrium each cycle, and to delete cells whose DNA is beyond repair. A clone that disables apoptosis survives insults that should have killed it, including chemotherapy and radiotherapy, which work partly by pushing damaged tumour cells into apoptosis. So "resistance to cell death" later in the hallmarks list is not abstract: it is a tumour that has switched off the very pathway our treatments rely on.

Driver, Passenger and Founder Events

If cancer needs several cooperating changes, the next question is which changes actually matter. Not all mutations are equal. A driver alteration gives a clone a selective advantage. A passenger alteration is carried along without major functional effect. A founder event is an early driver present in most cells of the tumour lineage.